Traditional type 1 diabetes therapies are prone to show poor glucose regulation especially in the postprandial period owing to both physiological and technological limitations. Although a closed-loop controller for glucose regulation has to be tuned to minimize the postprandial excursion and avoid late hypoglycemia, the intrinsic limitations of the problem lead to a trade-off between postprandial peak and late hypoglycemia risk. This paper reveals through an intensive in-silico study with multiple controller tuning combinations that a novel safety layer for glucose controllers, the so-called SAFE loop (Revert et al., 2013), not only reduces the hypoglycemia events but also allows reducing the postprandial glucose excursion, thus breaking th...
In order for an "artificial pancreas" to become a reality for ambulatory use, a practical closed-loo...
The first attempts for automated glucose control were made in the seventies of the last century. Now...
A control scheme was designed in order to reduce the risks of hyperglycemia and hypoglycemia in type...
Traditional type 1 diabetes therapies are prone to show poor glucose regulation especially in the po...
This paper addresses the design of blood glucose control during the postprandial period for Type 1 d...
Background: Time-varying dynamics is one of the main issues for achieving safe blood glucose control...
Background: Closed-loop (CL) insulin delivery systems utilizing proportional-integral-derivative (PI...
In the work presented in this dissertation, open-loop and closed-loop control strategies that were a...
Meal compensation in blood glucose control of people affected by type 1 Diabetes is an open challeng...
Post-prandial hypoglycemia occurs 2-5 hours after food intake, in not only insulin-treated patients ...
The aim of this pilot study was to test the feasibility of a bihormonal (glucagon and insulin) close...
Within the development of closed-loop glucose controllers, one of the major risks is insulin induced...
The objective of this work is to automatically regulate glycemia of Type 1 Diabetes Mellitus (T1DM) ...
International audienceThere is room for improvement in the algorithms used in closed-loop insulin th...
The artificial pancreas aims at the automatic delivery of insulin for glycemic control in patients w...
In order for an "artificial pancreas" to become a reality for ambulatory use, a practical closed-loo...
The first attempts for automated glucose control were made in the seventies of the last century. Now...
A control scheme was designed in order to reduce the risks of hyperglycemia and hypoglycemia in type...
Traditional type 1 diabetes therapies are prone to show poor glucose regulation especially in the po...
This paper addresses the design of blood glucose control during the postprandial period for Type 1 d...
Background: Time-varying dynamics is one of the main issues for achieving safe blood glucose control...
Background: Closed-loop (CL) insulin delivery systems utilizing proportional-integral-derivative (PI...
In the work presented in this dissertation, open-loop and closed-loop control strategies that were a...
Meal compensation in blood glucose control of people affected by type 1 Diabetes is an open challeng...
Post-prandial hypoglycemia occurs 2-5 hours after food intake, in not only insulin-treated patients ...
The aim of this pilot study was to test the feasibility of a bihormonal (glucagon and insulin) close...
Within the development of closed-loop glucose controllers, one of the major risks is insulin induced...
The objective of this work is to automatically regulate glycemia of Type 1 Diabetes Mellitus (T1DM) ...
International audienceThere is room for improvement in the algorithms used in closed-loop insulin th...
The artificial pancreas aims at the automatic delivery of insulin for glycemic control in patients w...
In order for an "artificial pancreas" to become a reality for ambulatory use, a practical closed-loo...
The first attempts for automated glucose control were made in the seventies of the last century. Now...
A control scheme was designed in order to reduce the risks of hyperglycemia and hypoglycemia in type...